Vincent Ribrag
Inserm(FR)Université Paris-Saclay(FR)Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Immune-related adverse events with immune checkpoint blockade: a comprehensive review(2016)2,094 cited
- → Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma(2017)971 cited
- → High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial(2017)760 cited
- → Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study(2018)601 cited
- → Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma(2017)402 cited
- → Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network